NCT03005002View on ClinicalTrials.gov

Durvalumab and Tremelimumab in Treating Patients With Microsatellite Stable Metastatic Colorectal Cancer to the Liver

PHASE1CompletedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

June 28, 2017

Primary Completion Date

November 26, 2019

Study Completion Date

November 26, 2019

Conditions
Metastatic Carcinoma in the LiverMLH1 Gene MutationMSH6 Gene MutationPMS2 Gene MutationStage IV Colorectal CancerStage IVA Colorectal CancerStage IVB Colorectal Cancer
Interventions
BIOLOGICAL

Durvalumab

Given IV

OTHER

Laboratory Biomarker Analysis

Correlative studies

BIOLOGICAL

Tremelimumab

Given IV

Trial Locations (1)

91010

City of Hope Medical Center, Duarte

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

City of Hope Medical Center

OTHER

NCT03005002 - Durvalumab and Tremelimumab in Treating Patients With Microsatellite Stable Metastatic Colorectal Cancer to the Liver | Biotech Hunter | Biotech Hunter